Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+tumor infiltrating lymphocytes in ductal and lobular breast cancers

Authors: Raoul Droeser, Inti Zlobec, Ergin Kilic, Uwe Güth, Michael Heberer, Giulio Spagnoli, Daniel Oertli, Coya Tapia

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controversial. Here, we used a tumor microarray including a large series of ductal and lobular breast cancers with long term follow up data, to analyze clinical impact of TIL expressing specific phenotypes and distribution of TILs within different tumor compartments and in different histological subtypes.

Methods

A tissue microarray (TMA) including 894 ductal and 164 lobular breast cancers was stained with antibodies recognizing CD4, FOXP3, and IL-17 by standard immunohistochemical techniques. Lymphocyte counts were correlated with clinico-pathological parameters and survival.

Results

CD4+ lymphocytes were more prevalent than FOXP3+ TILs whereas IL-17+ TILs were rare. Increased numbers of total CD4+ and FOXP3+ TIL were observed in ductal, as compared with lobular carcinomas. High grade (G3) and estrogen receptor (ER) negative ductal carcinomas displayed significantly (p < 0.001) higher CD4+ and FOXP3+ lymphocyte infiltration while her2/neu over-expression in ductal carcinomas was significantly (p < 0.001) associated with higher FOXP3+ TIL counts. In contrast, lymphocyte infiltration was not linked to any clinico-pathological parameters in lobular cancers. In univariate but not in multivariate analysis CD4+ infiltration was associated with significantly shorter survival in patients bearing ductal, but not lobular cancers. However, a FOXP3+/CD4+ ratio > 1 was associated with improved overall survival even in multivariate analysis (p = 0.033).

Conclusions

Ductal and lobular breast cancers appear to be infiltrated by different lymphocyte subpopulations. In ductal cancers increased CD4+ and FOXP3+ TIL numbers are associated with more aggressive tumor features. In survival analysis, absolute numbers of TILs do not represent major prognostic indicators in ductal and lobular breast cancer. Remarkably however, a ratio > 1 of total FOXP3+/CD4+ TILs in ductal carcinoma appears to represent an independent favorable prognostic factor.
Appendix
Available only for authorised users
Literature
1.
Takagi S, Chen K, Schwarz R, Iwatsuki S, Herberman RB, Whiteside TL: Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer. 1989, 63: 102-111. 10.1002/1097-0142(19890101)63:1<102::AID-CNCR2820630117>3.0.CO;2-T.CrossRefPubMed
2.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139.CrossRefPubMed
3.
Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G: Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol. 2010, 184: 1630-1641. 10.4049/jimmunol.0902813.CrossRefPubMed
4.
Luscher U, Filgueira L, Juretic A, Zuber M, Luscher NJ, Heberer M, et al: The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer. 1994, 57: 612-619. 10.1002/ijc.2910570428.CrossRefPubMed
5.
Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, et al: Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004, 64: 2865-2873. 10.1158/0008-5472.CAN-03-3066.CrossRefPubMed
6.
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008, 8: 299-308. 10.1038/nrc2355.CrossRefPubMedPubMedCentral
7.
Oble DA, Loewe R, Yu P, Mihm MC: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 2009, 9: 3-PubMedPubMedCentral
8.
9.
Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007, 8: 345-350.CrossRefPubMed
10.
Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al: Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008, 112: 362-373. 10.1182/blood-2007-11-120998.CrossRefPubMedPubMedCentral
11.
Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, et al: Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999, 59: 3698-3704.PubMed
12.
Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al: IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011, 407: 348-354. 10.1016/j.bbrc.2011.03.021.CrossRefPubMed
13.
Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, et al: Th17 cells in cancer: help or hindrance?. Carcinogenesis. 2011, 32: 643-649. 10.1093/carcin/bgr019.CrossRefPubMedPubMedCentral
14.
Ferguson DJ: Intraepithelial lymphocytes and macrophages in the normal breast17. Virchows Arch A Pathol Anat Histopathol. 1985, 407: 369-378. 10.1007/BF00709984.CrossRefPubMed
15.
Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S: Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch. 2005, 446: 10-14. 10.1007/s00428-004-1143-9.CrossRefPubMed
16.
Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, et al: Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001, 7: 3025-3030.PubMed
17.
Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J: Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res. 1992, 12: 1463-1466.PubMed
18.
Murta EF, de Andrade JM, Falcao RP, Bighetti S: Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori. 2000, 86: 403-407.PubMed
19.
Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al Tweigeri T, Dermime S: FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008, 8: 57-10.1186/1471-2407-8-57.CrossRefPubMedPubMedCentral
20.
Lim KH, Telisinghe PU, Abdullah MS, Ramasamy R: Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun. 2010, 10: 3-PubMedPubMedCentral
21.
Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, et al: The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 2009, 29: 2445-2451.PubMed
22.
Macchetti AH, Marana HR, Silva JS, de Andrade JM, Ribeiro-Silva A, Bighetti S: Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics (Sao Paulo). 2006, 61: 203-208.
23.
Rakha EA, Aleskandarany M, El Sayed ME, Blamey RW, Elston CW, Ellis IO, et al: The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer. 2009, 45: 1780-1787. 10.1016/j.ejca.2009.02.014.CrossRefPubMed
24.
Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD: Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology. 2011, 58: 1107-1116.PubMed
25.
Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010, 28: 105-113. 10.1200/JCO.2009.23.7370.CrossRefPubMed
26.
Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, et al: FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009, 27: 1746-1752. 10.1200/JCO.2008.17.9036.CrossRefPubMed
27.
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006, 24: 5373-5380. 10.1200/JCO.2006.05.9584.CrossRefPubMed
28.
Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, et al: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res. 2008, 14: 2413-2420. 10.1158/1078-0432.CCR-07-4491.CrossRefPubMed
29.
Tapia C, Zlobec I, Schneider S, Kilic E, Guth U, Bubendorf L, et al: Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol. 2011, 42: 983-990. 10.1016/j.humpath.2010.10.012.CrossRefPubMedPubMedCentral
30.
Guth U, Huang DJ, Schotzau A, Dirnhofer S, Wight E, Singer G: Breast cancer with non-inflammatory skin involvement: current data on an underreported entity and its problematic classification. Breast. 2010, 19: 59-64. 10.1016/j.breast.2009.11.008.CrossRefPubMed
31.
Sauter G, Simon R, Hillan K: Tissue microarrays in drug discovery. Nat Rev Drug Discov. 2003, 2: 962-972. 10.1038/nrd1254.CrossRefPubMed
32.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
33.
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005, 353: 2654-2666. 10.1056/NEJMoa051424.CrossRefPubMed
34.
Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, et al: Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res. 1997, 3: 817-819.PubMed
35.
de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, et al: The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res. 2010, 16: 1272-1280. 10.1158/1078-0432.CCR-09-1844.CrossRefPubMed
36.
Colleoni M, Viale G, Goldhirsch A: Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast. 2009, 18: (Suppl 3):S137-S140-
37.
Cowin P, Rowlands TM, Hatsell SJ: Cadherins and catenins in breast cancer. Curr Opin Cell Biol. 2005, 17: 499-508. 10.1016/j.ceb.2005.08.014.CrossRefPubMed
38.
Bohling SD, Allison KH: Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol. 2008, 21: 1527-1532. 10.1038/modpathol.2008.160.CrossRefPubMed
39.
Minervini A, Di Cristofano C, Gacci M, Serni S, Menicagli M, Lanciotti M, et al: Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers. J Urol. 2008, 180: 1284-1289. 10.1016/j.juro.2008.06.036.CrossRefPubMed
40.
Finger EC, Giaccia AJ: Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010, 29: 285-293. 10.1007/s10555-010-9224-5.CrossRefPubMedPubMedCentral
41.
Osinsky S, Zavelevich M, Vaupel P: Tumor hypoxia and malignant progression. Exp Oncol. 2009, 31: 80-86.PubMed
42.
De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer. 2005, 5: 42-10.1186/1471-2407-5-42.CrossRefPubMedPubMedCentral
43.
Ben Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J: Hypoxia controls CD4+ CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol. 2008, 38: 2412-2418. 10.1002/eji.200838318.CrossRefPubMed
44.
Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al: Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009, 27: 186-192. 10.1200/JCO.2008.18.7229.CrossRefPubMed
45.
Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, et al: High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer. 2010, 126: 2635-2643.PubMed
46.
Roncarolo MG, Gregori S: Is FOXP3 a bona fide marker for human regulatory T cells?. Eur J Immunol. 2008, 38: 925-927. 10.1002/eji.200838168.CrossRefPubMed
47.
Siegmund K, Ruckert B, Ouaked N, Burgler S, Speiser A, Akdis CA, et al: Unique phenotype of human tonsillar and in vitro-induced FOXP3+CD8+ T cells. J Immunol. 2009, 182: 2124-2130. 10.4049/jimmunol.0802271.CrossRefPubMed
48.
Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, et al: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 2007, 67: 8344-8350. 10.1158/0008-5472.CAN-06-3304.CrossRefPubMed
49.
Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, et al: FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007, 129: 1275-1286. 10.1016/j.cell.2007.04.034.CrossRefPubMedPubMedCentral
50.
Kim J, Lahl K, Hori S, Loddenkemper C, Chaudhry A, deRoos P, et al: Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol. 2009, 183: 7631-7634. 10.4049/jimmunol.0804308.CrossRefPubMed
51.
Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F, et al: Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011, 125: 65-72. 10.1007/s10549-010-0831-1.CrossRefPubMed
52.
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, et al: An evaluation of the clinical significance of FOXP3(+) infiltrating cells in human breast cancer. Breast cancer Res Treat. 2011, 127: 99-108. 10.1007/s10549-010-0987-8.CrossRefPubMed
53.
Gobert M, Treilleux I, driss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al: Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69: 2000-2009. 10.1158/0008-5472.CAN-08-2360.CrossRefPubMed
54.
Menetrier-Caux C, Gobert M, Caux C: Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res. 2009, 69: 7895-7898. 10.1158/0008-5472.CAN-09-1642.CrossRefPubMed
55.
Wolf D, Wolf AM, Tzankov A: Comment on "Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice". J Immunol. 2010, 184: 4051-CrossRefPubMed
Metadata
Title
Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+tumor infiltrating lymphocytes in ductal and lobular breast cancers
Authors
Raoul Droeser
Inti Zlobec
Ergin Kilic
Uwe Güth
Michael Heberer
Giulio Spagnoli
Daniel Oertli
Coya Tapia
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-134

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery

Research article

Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells

Research article

The TERT rs2736100 Polymorphism and Cancer Risk: A Meta-analysis Based on 25 Case-Control Studies

Research article

The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy

Research article

LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro

Case report

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits